In view of the above experimental results, although the mechanism of the effect of the cGAS–STING pathway on fatty liver (including NAFLD and ALD) is not fully elucidated, it is possible to suggest that the cGAS–STING pathway could be a potential therapeutic target for the treatment of fatty liver. Here, CGAS is linked to metabolic dysfunction-associated steatotic liver disease.